These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 27842569)

  • 41. A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal.
    Cruickshank CC; Montebello ME; Dyer KR; Quigley A; Blaszczyk J; Tomkins S; Shand D
    Drug Alcohol Rev; 2008 May; 27(3):326-33. PubMed ID: 18368615
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Substitution therapy tested against amphetamine dependence].
    Bloniecki Kallio V; Guterstam J; Franck J
    Lakartidningen; 2016 Jan; 113():. PubMed ID: 26756343
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Review of Methamphetamine Dependence and Withdrawal Treatment: A Focus on Anxiety Outcomes.
    Hellem TL
    J Subst Abuse Treat; 2016 Dec; 71():16-22. PubMed ID: 27776672
    [TBL] [Abstract][Full Text] [Related]  

  • 44. NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines.
    National Toxicology Program
    NTP CERHR MON; 2005 Jul; (16):vii-III1. PubMed ID: 16130031
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Study protocol: a dose-escalating, phase-2 study of oral lisdexamfetamine in adults with methamphetamine dependence.
    Ezard N; Dunlop A; Clifford B; Bruno R; Carr A; Bissaker A; Lintzeris N
    BMC Psychiatry; 2016 Dec; 16(1):428. PubMed ID: 27905916
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Topiramate for the management of methamphetamine dependence: a pilot randomized, double-blind, placebo-controlled trial.
    Rezaei F; Ghaderi E; Mardani R; Hamidi S; Hassanzadeh K
    Fundam Clin Pharmacol; 2016 Jun; 30(3):282-9. PubMed ID: 26751259
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bupropion for the treatment of methamphetamine dependence.
    Elkashef AM; Rawson RA; Anderson AL; Li SH; Holmes T; Smith EV; Chiang N; Kahn R; Vocci F; Ling W; Pearce VJ; McCann M; Campbell J; Gorodetzky C; Haning W; Carlton B; Mawhinney J; Weis D
    Neuropsychopharmacology; 2008 Apr; 33(5):1162-70. PubMed ID: 17581531
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis.
    McIntyre RS; Lee Y; Zhou AJ; Rosenblat JD; Peters EM; Lam RW; Kennedy SH; Rong C; Jerrell JM
    J Clin Psychopharmacol; 2017 Aug; 37(4):412-418. PubMed ID: 28590365
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patterns of reduced use and abstinence in multi-site randomized controlled trials of pharmacotherapies for cocaine and methamphetamine use disorders.
    Amin-Esmaeili M; Susukida R; Johnson RM; Farokhnia M; Crum RM; Thrul J; Mojtabai R
    Drug Alcohol Depend; 2021 Sep; 226():108904. PubMed ID: 34304121
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Placebo-group responders in methamphetamine pharmacotherapy trials: the role of immediate establishment of abstinence.
    Brensilver M; Heinzerling KG; Swanson AN; Shoptaw SJ
    Exp Clin Psychopharmacol; 2012 Oct; 20(5):430-5. PubMed ID: 22867036
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evidence-Based Guidelines for the Pharmacologic Management of Methamphetamine Dependence, Relapse Prevention, Chronic Methamphetamine-Related, and Comorbid Psychiatric Disorders in Post-Acute Settings.
    Härtel-Petri R; Krampe-Scheidler A; Braunwarth WD; Havemann-Reinecke U; Jeschke P; Looser W; Mühlig S; Schäfer I; Scherbaum N; Bothe L; Schaefer C; Hamdorf W
    Pharmacopsychiatry; 2017 May; 50(3):96-104. PubMed ID: 28445899
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does chronic use of amphetamine-type stimulants impair interference control? - A meta-analysis.
    Opitz A; Petasch MS; Klappauf R; Kirschgens J; Hinz J; Dittmann L; Dathe AS; Quednow BB; Beste C; Stock AK
    Neurosci Biobehav Rev; 2023 Mar; 146():105020. PubMed ID: 36581170
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacotherapy for amphetamine dependence: A systematic review.
    Lee NK; Jenner L; Harney A; Cameron J
    Drug Alcohol Depend; 2018 Oct; 191():309-337. PubMed ID: 30173086
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk of stroke in prescription and other amphetamine-type stimulants use: A systematic review.
    Indave BI; Sordo L; Bravo MJ; Sarasa-Renedo A; Fernández-Balbuena S; De la Fuente L; Sonego M; Barrio G
    Drug Alcohol Rev; 2018 Jan; 37(1):56-69. PubMed ID: 28485090
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Methamphetamine-associated cardiomyopathy: an addiction medicine perspective.
    Somma V; Osekowski M; Paratz E; Bonomo Y
    Intern Med J; 2023 Jan; 53(1):21-26. PubMed ID: 36693638
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Which individual, social and environmental influences shape key phases in the amphetamine type stimulant use trajectory? A systematic narrative review and thematic synthesis of the qualitative literature.
    O'Donnell A; Addison M; Spencer L; Zurhold H; Rosenkranz M; McGovern R; Gilvarry E; Martens MS; Verthein U; Kaner E
    Addiction; 2019 Jan; 114(1):24-47. PubMed ID: 30176077
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacological approaches to methamphetamine dependence: a focused review.
    Karila L; Weinstein A; Aubin HJ; Benyamina A; Reynaud M; Batki SL
    Br J Clin Pharmacol; 2010 Jun; 69(6):578-92. PubMed ID: 20565449
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Barriers to accessing methamphetamine treatment: A systematic review and meta-analysis.
    Cumming C; Troeung L; Young JT; Kelty E; Preen DB
    Drug Alcohol Depend; 2016 Nov; 168():263-273. PubMed ID: 27736680
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Methamphetamine exposure and depression-A systematic review and meta-analysis.
    Leung J; Mekonen T; Wang X; Arunogiri S; Degenhardt L; McKetin R
    Drug Alcohol Rev; 2023 Sep; 42(6):1438-1449. PubMed ID: 37126460
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prescription psychostimulants as a harm reduction and treatment intervention for methamphetamine use disorder and the implications for nursing clinical practice: A scoping review of the literature.
    Leidl D; Takhar P; Li H
    Int J Ment Health Nurs; 2023 Oct; 32(5):1225-1242. PubMed ID: 36978242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.